Evaluation of coagulation function by rotation thromboelastometry in critically ill patients with severe COVID-19 pneumonia

被引:0
|
作者
Vittorio Pavoni
Lara Gianesello
Maddalena Pazzi
Caterina Stera
Tommaso Meconi
Francesca Covani Frigieri
机构
[1] Santa Maria Annunziata Hospital,Emergency Department and Critical Care Area, Anesthesia and Intensive Care Unit
[2] University-Hospital Careggi,Department of Anesthesia and Intensive Care, Orthopedic Anesthesia
来源
Journal of Thrombosis and Thrombolysis | 2020年 / 50卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Critically ill patients with COVID-19 pneumonia suffered both high thrombotic and bleeding risk. The effect of SARS-CoV-2 on coagulation and fibrinolysis is not well known. We conducted a retrospective study of critically ill patients admitted to an intensive care unit (ICU) a cause of severe COVID-19 pneumonia and we evaluated coagulation function using rotational thromboelastometry (ROTEM) on day of admission (T0) and 5 (T5) and 10 (T10) days after admission to ICU. Coagulation standard parameters were also evaluated. Forty patients were enrolled into the study. The ICU and the hospital mortality were 10% and 12.5%, respectively. On ICU admission, prothrombin time was slightly reduced and it increased significantly at T10 (T0 = 65.1 ± 9.8 vs T10 = 85.7 ± 1.5, p = 0.002), while activated partial thromboplastin time and fibrinogen values were higher at T0 than T10 (32.2 ± 2.9 vs 27.2 ± 2.1, p = 0.017 and 895.1 ± 110 vs 332.5 ± 50, p = 0.002, respectively); moreover, whole blood thromboelastometry profiles were consistent with hypercoagulability characterized by an acceleration of the propagation phase of blood clot formation [i.e., CFT below the lower limit in INTEM 16/40 patients (40%) and EXTEM 20/40 patients (50%)] and significant higher clot strength [MCF above the upper limit in INTEM 20/40 patients (50%), in EXTEM 28/40 patients (70%) and in FIBTEM 29/40 patients (72.5%)]; however, this hypercoagulable state persists in the first five days, but it decreases ten day after, without returning to normal values. No sign of secondary hyperfibrinolysis or sepsis induced coagulopathy (SIC) were found during the study period. In six patients (15%) a deep vein thrombosis and in 2 patients (5%) a thromboembolic event, were found; 12 patients (30%) had a catheter-related thrombosis. ROTEM analysis confirms that patients with severe COVID-19 pneumonia had a hypercoagulation state that persisted over time.
引用
收藏
页码:281 / 286
页数:5
相关论文
共 50 条
  • [31] The Effectiveness of Bevacizumab in COVID-19 Pneumonia Among Critically Ill Patients
    Rajachandran, Karthikkeyan
    Varghese, Giphy Susan
    Kumar, J. Vinoth
    Raja, Santhosh
    Chandran, S. K. Jagadish
    Aruloli, M.
    Murali, A.
    EGYPTIAN JOURNAL OF CRITICAL CARE MEDICINE, 2022, 9 (03): : 79 - 84
  • [32] Major bleeding complications in critically ill patients with COVID-19 pneumonia
    Anne Godier
    Darless Clausse
    Simon Meslin
    Myriame Bazine
    Elodie Lang
    Florian Huche
    Bernard Cholley
    Sophie Rym Hamada
    Journal of Thrombosis and Thrombolysis, 2021, 52 : 18 - 21
  • [33] Bacterial Pneumonia in COVID-19 Critically Ill Patients: A Case Series
    Dudoignon, Emmanuel
    Camelena, Francois
    Deniau, Benjamin
    Habay, Adrien
    Coutrot, Maxime
    Ressaire, Quentin
    Plaud, Benoit
    Bercot, Beatrice
    Depret, Francois
    CLINICAL INFECTIOUS DISEASES, 2021, 72 (05) : 905 - 906
  • [34] Major bleeding complications in critically ill patients with COVID-19 pneumonia
    Godier, Anne
    Clausse, Darless
    Meslin, Simon
    Bazine, Myriame
    Lang, Elodie
    Huche, Florian
    Cholley, Bernard
    Hamada, Sophie Rym
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2021, 52 (01) : 18 - 21
  • [35] Invasive fusariosis in a critically ill patient with severe COVID-19 pneumonia: A case report
    Barberis, Fernanda
    Benedetti, Maria F.
    de Abreu, Mariela S.
    Pola, Santiago J.
    Posse, Gladys
    Capece, Paula
    Fernandez Lausi, Adriana
    Nusblat, Alejandro
    Cuestas, Maria L.
    MEDICAL MYCOLOGY CASE REPORTS, 2022, 35 : 5 - 8
  • [36] EVALUATION OF THE EFFICACY OF TOCILIZUMAB IN CRITICALLY ILL COVID-19 PATIENTS
    Riggs, Kayla
    Patel, Vishal
    Pittiglio, Marina
    Cavanaugh, Joseph
    Sullivan, Jesse
    CRITICAL CARE MEDICINE, 2021, 49 (01) : 141 - 141
  • [37] Risk factors for severe and critically ill COVID-19 patients: A review
    Gao, Ya-dong
    Ding, Mei
    Dong, Xiang
    Zhang, Jin-jin
    Azkur, Ahmet Kursat
    Azkur, Dilek
    Gan, Hui
    Sun, Yuan-li
    Fu, Wei
    Li, Wei
    Liang, Hui-ling
    Cao, Yi-yuan
    Yan, Qi
    Cao, Can
    Gao, Hong-yu
    Bruggen, Marie-Charlotte
    van de Veen, Willem
    Sokolowska, Milena
    Akdis, Mubeccel
    Akdis, Cezmi A.
    ALLERGY, 2021, 76 (02) : 428 - 455
  • [38] Severe mold fungal infections in critically ill patients with COVID-19
    Koulenti, Despoina
    Paramythiotou, Elisabeth
    Almyroudi, Maria Panagiota
    Karvouniaris, Marios
    Markou, Nikolaos
    Paranos, Paschalis
    Routsi, Christina
    Meletiadis, Joseph
    Blot, Stijn
    FUTURE MICROBIOLOGY, 2024, 19 (08) : 697 - 714
  • [39] Severe acute kidney injury in critically ill COVID-19 patients
    Gaston J. Piñeiro
    Alicia Molina-Andújar
    Evelyn Hermida
    Miquel Blasco
    Luis F. Quintana
    Guido Muñoz Rojas
    Jordi Mercadal
    Pedro Castro
    Elena Sandoval
    Rut Andrea
    Javier Fernández
    Joan Ramon Badia
    Alex Soriano
    Esteban Poch
    Journal of Nephrology, 2021, 34 : 285 - 293
  • [40] Severe acute kidney injury in critically ill COVID-19 patients
    Pineiro, Gaston J.
    Molina-Andujar, Alicia
    Hermida, Evelyn
    Blasco, Miquel
    Quintana, Luis F.
    Rojas, Guido Munoz
    Mercadal, Jordi
    Castro, Pedro
    Sandoval, Elena
    Andrea, Rut
    Fernandez, Javier
    Badia, Joan Ramon
    Soriano, Alex
    Poch, Esteban
    JOURNAL OF NEPHROLOGY, 2021, 34 (02) : 285 - 293